Table 2 DAS28, CD 19+ cell count, CD4+ cell count at baseline, post treatment (M3/M6) and at the time of retreatment during the first cycle in 32 patients who received a second cycle of rituximab

Men (n = 7)

5.4 (4.1–6.0)

4.4 (2.0–5.1)

3.8 (3.2–5.3)

180 (45–237)

9 (0–87)*

50 (3–138)*

962 (703–1047)

652 (393–853)

1146 (702–1412)

Women (n = 25)

5.2 (4.6–6.2)

3.3 (2.7–4.7)**

4.6 (3.8–5.9)**

320 (179–411)

3 (0–36)**

44 (11–171)**

1329 (1015–1873)

988 (772–1498)**

1325 (964–1549)*

RF + (n = 22)

5.3 (4.3–6.1)

3.6 (2.6–5.1)**

4.3 (3.5–5.5)

271 (124–387)

3 (0–21)**

47 (10–134)**

1041 (908–1640)

875 (603–1305)*

1033 (826–1513)

RF – (n = 10)

5.2 (4.7–6.3)

3.3 (3.1–4.6)*

4.6 (3.6–5.8)*

275 (191–386)

15 (0–55)**

45 (8–263)*

1442 (1121–2048)

1044 (864–1386)**

1376 (1212–1637)*

Erosion (n = 24)

5.8 (4.3–6.4)

3.7 (2.6–5.1)**

4.6 (3.5–5.8)*

233 (143–325)

3 (0–40)**

47 (7–131)**

1119 (953–1708)

998 (639–1514)**

1328 (927–1584)*

No erosion (n = 8)

5.0 (4.7–5.3)

3.4 (2.7–4.3)*

4.2 (3.5–5.4)

371 (147–541)

4 (1–38)

100 (22–229)*

1289 (912–2201)

939 (869–981)*

1112 (958–1345)*

TNFi (n = 27)

5.2 (4.5–6.3)

3.6 (2.7–5.0)**

4.3 (3.4–5.8)*

237 (141–332)

3 (0–30)**

44 (9–138)**

1248 (995–1732)

988 (652–1464)**

1331 (1029–1620)*

No TNFi (n = 5)

5.8 (4.4–6.0)

2.8 (2.4–5.0)

4.4 (3.9–5.0)

433 (244–523)

3 (1–256)

68 (8–360)

819 (739–1733)

691 (323–907)

918 (727–981)